NSC-38877 |
LIALDA |
SFROWASA |
IPOCOL |
ROWASA |
MESALAZINE |
FISALAMINE |
APRISO |
MEZAVANT XL |
DELZICOL |
SALOFALK |
CANASA |
PENTASA |
MESALAZINE |
MESREN MR |
MESALAMINE |
ASACOL HD |
PENTASA SR |
ASACOL |
MAX-002 |
OCTASA |
COLTEC EC |
P-AMINOSALICYLSAEURE |
3-CARBOXY-4-HYDROXYANILINE |
MESALAZINA |
M-AMINOSALICYLIC ACID |
PENTASA® |
5-ASA |
5-AMINOSALICYLATE |
MESALAZINUM |
5-AMINOSALICYLIC ACID |
MÉSALAZINE |
chembl:CHEMBL704 |
chemidplus:89-57-6 |
pubchem.compound:4075 |
drugbank:00244 |
rxcui:52582 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | for treatment of ulcerative proctitis |
Year of Approval | 1987 |
Drug Class | anti-inflammatory agents, non-steroidal |
Drug Indications | for treatment of ulcerative colitis |
Drug Indications | antiinflammatory agent |
inhibitor (inhibitory) |
Trial Name | SPD476,Lialda |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | MAX-002 |
Novel drug target | Established target |
Mechanism of Interaction | Arachidonate 5-lipoxygenase inhibitor |
inhibitor (inhibitory) |
Trial Name | SPD476,Lialda |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | MAX-002 |
Novel drug target | Established target |
Trial Name | mesalamine,Pentasa, Canasa, Asacol |
inhibitor (inhibitory) |
Trial Name | MAX-002 |
Novel drug target | Established target |
Trial Name | mesalamine,Pentasa, Canasa, Asacol |
agonist (activating) |
Novel drug target | Established target |
Trial Name | MAX-002 |
Mechanism of Interaction | Peroxisome proliferator-activated receptor gamma agonist |
MESALAZINE | Primary Drug Name |
Drug Class | anti-inflammatory agents, non-steroidal |
Year of Approval | 1987 |
Drug Indications | antiinflammatory agent |
Drug Class | Small molecule |
FDA Approval | approved |
Drug Indications | for treatment of ulcerative proctitis |
Drug Class | Small Molecule |
FDA Approval | approved |
C29249 | NCI drug code |
CHEMBL704 | ChEMBL Drug ID |
D0C4YC | TTD Drug ID |